无创正压通气联合前列地尔在COPD合并PH患者中的应用效果

打开文本图片集

[Abstract] Objective：To investigate the eect of non-invasive positive pressure ventilation （NIPPV） combined with prostaglandin in patients with COPD combined with pulmonary hypertension （PH）.Method： A totalof 89 patients with COPD combined withPHadmited to from March 2023 toMarch 2O24weredivided into the control group（ n =44，conventional basic treatment + Alprostadil） and the observation group （ n =45，combined with NIPPV on the basis of the control group）according to the method of random arrangement table，the haemodynamics，serum inflammatory factor levels，arterial blood gas indexes，lung function and pulmonary vascular function of the two groups were assessd and compared. Result： Before treatment， mean pulmonary arterial pressure （MPAP）， mean systemic arterial pressure （MSAP），pulmonary vascular resistance （PVR）， （20 FEV1 ， FVC， CRP， IL-6， TNF- α ， Pa02 ， PaCO2 Sa02 ，pulmonary vascular compliance （Cpv） and total pulmonary vascularresistance （TPR） were compared between the two groups，the differences were not statisticallysignificant 0 P> 0.05）.After treatment，the Pa02 Sa02 FEV1 ，FVCand Cpv in the observation groupwere higher than those in the control group，and MPAP，MSAP，PVR， CRP，IL-6，TNF- α PaCO2 and TPR were lower than those in the control group，the differences were statistically significant （ P<0.05 ）.Conclusion：NIPPV combined with Alprostadil can effectivelyreduce the levels of MPAPand serum inflammatory factors in patients with COPDcombined with PH，and improve the patients'arterial blood gas indexes，lung function and pulmonary vascular function.

[Keywords] Non-invasive positive pressure ventilation Alprostadil COPD combined with pulmonary hypertensionMean pulmonary arterial pressure

-author's address：Department of Respiratory and Critical Care Medicine， ，Nanping3542oo，China doi：10.3969/j.issn.1674-4985.2025.21.005

COPD是一类以气流受限且不完全可逆为主要临床特征的多发慢性气道疾病，具有高发病率、高致残率等显著特点[1-2]。（剩余7445字）